Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?
作者信息
dos Santos Rodrigo Pires, Jacoby Thalita, Goldani Luciano Zubaran
出版信息
Antimicrob Agents Chemother. 2010 Jul;54(7):3076; author reply 3076-7. doi: 10.1128/AAC.00472-10.
Abstract
摘要
相似文献
1
Antimicrobial stewardship lessons: do Pseudomonas-sparing agents, such as ertapenem, effectively improve bacterial resistance?
Antimicrob Agents Chemother. 2010 Jul;54(7):3076; author reply 3076-7. doi: 10.1128/AAC.00472-10.
2
Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 Dec;53(12):5122-6. doi: 10.1128/AAC.00064-09. Epub 2009 Sep 28.
3
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
Int J Antimicrob Agents. 2012 Jan;39(1):11-5. doi: 10.1016/j.ijantimicag.2011.08.018. Epub 2011 Nov 1.
4
The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
Infect Control Hosp Epidemiol. 2009 May;30(5):487-90. doi: 10.1086/596781.
5
Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
Antimicrob Agents Chemother. 2011 Dec;55(12):5597-601. doi: 10.1128/AAC.00742-11. Epub 2011 Oct 3.
6
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
Antimicrob Agents Chemother. 2013 Feb;57(2):1086-8. doi: 10.1128/AAC.01748-12. Epub 2012 Dec 17.
7
Influence of ertapenem administration on the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Braz J Infect Dis. 2008 Apr;12(2):105-6. doi: 10.1590/s1413-86702008000200001.
8
The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
Diagn Microbiol Infect Dis. 2011 Jul;70(3):367-72. doi: 10.1016/j.diagmicrobio.2011.03.009.
9
Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
Infect Control Hosp Epidemiol. 2010 May;31(5):485-90. doi: 10.1086/652154.
10
Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
J Antimicrob Chemother. 2013 Aug;68(8):1917-25. doi: 10.1093/jac/dkt091. Epub 2013 Apr 4.
本文引用的文献
1
Impact of hospital-wide infection rate, invasive procedures use and antimicrobial consumption on bacterial resistance inside an intensive care unit.
J Hosp Infect. 2010 May;75(1):23-7. doi: 10.1016/j.jhin.2009.11.021. Epub 2010 Mar 24.
2
Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 Dec;53(12):5122-6. doi: 10.1128/AAC.00064-09. Epub 2009 Sep 28.
3
The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
Infect Control Hosp Epidemiol. 2009 May;30(5):487-90. doi: 10.1086/596781.
4
Methods for estimating confidence intervals in interrupted time series analyses of health interventions.
J Clin Epidemiol. 2009 Feb;62(2):143-8. doi: 10.1016/j.jclinepi.2008.08.007. Epub 2008 Nov 17.
5
Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem.
J Infect. 2008 Aug;57(2):123-7. doi: 10.1016/j.jinf.2008.06.001. Epub 2008 Jul 21.
6
Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies.
Clin Infect Dis. 2007 Oct 1;45(7):901-7. doi: 10.1086/521255. Epub 2007 Aug 23.
7
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems.
J Antimicrob Chemother. 2005 Mar;55(3):306-11. doi: 10.1093/jac/dki009. Epub 2005 Feb 10.
8
Segmented regression analysis of interrupted time series studies in medication use research.
J Clin Pharm Ther. 2002 Aug;27(4):299-309. doi: 10.1046/j.1365-2710.2002.00430.x.
Zotero 插件